PLRX compared with BOLD: revenue, margins and what each company keeps, and the suppliers and customers both name

PLRXPliant Therapeutics, Inc.

Mkt capRevenueRevenue

BOLDBoundless Bio, Inc.

Mkt capRevenueRevenue

Compare

PLRXPliant Therapeutics, Inc.

BOLDBoundless Bio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

PLRX, solidBOLD, dashed

Supply-chain overlap

Revenue flow

PLRX: latest quarter is a loss; flow not drawable. BOLD: latest quarter not drawable.Method ›

PLRXPliant Therapeutics, Inc.

0.85▼−1.58%· post 0.85

Mkt cap$53.2MRevenue$248,000Q2 FY23

BOLDBoundless Bio, Inc.

2.45▼−1.21%· post 2.45

ClosedOct 30 '26

Mkt cap$56.2MRevenue—

Compare

ClosedOct 30 '26

PLRXPliant Therapeutics, Inc.

BOLDBoundless Bio, Inc.

0.85▼−1.58%post 0.85

Price

2.45▼−1.21%post 2.45

$53.2M

Mkt cap

$56.2M

Q2 FY23$248,000

Revenue

—

PLRX0.85▼−1.58%vsBOLD2.45▼−1.21%ClosedOct 30 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only PLRX 1

NVSNovartissupplier

Shared 0

No disclosed counterparties: BOLD.

Only BOLD 0

None

Role chip = supplier or customerSource: SEC EDGAR